Containing Designated Ingredient To Stabilize An Active Ingredient Patents (Class 514/970)
Cross-Reference Art Collections
-
Patent number: 6403533Abstract: A method for stabilizing dilute solutions of 3-isothiazolone compounds against the formation of unwanted brown precipitate in the presence of low levels of copper, by the addition of 2 to 50% of selected water-soluble organic solvents, is disclosed. The aqueous solutions are substantially free of metal nitrate, metal nitrite and magnesium salt stabilizers.Type: GrantFiled: January 12, 2001Date of Patent: June 11, 2002Assignee: Rohm and Haas CompanyInventor: Beverly Jean El A'mma
-
Patent number: 6395765Abstract: Composition which is useful in particular for the treatment and protection of domestic animals which are infested with parasites or are likely to be infested with them, these compositions comprising, in the form of a ready-to-use solution: a) an insecticidal active substance of formula (I), b) a crystallization inhibitor, c) an organic solvent having a dielectric constant of between 10 and 35, preferably of between 20 and 30, d) an organic co-solvent having a boiling point below 100° C., preferably below 80° C., and a dielectric constant of between 10 and 40, preferably of between 20 and 30.Type: GrantFiled: September 25, 1996Date of Patent: May 28, 2002Assignee: MerialInventor: Jean Pierre Etchegaray
-
Patent number: 6379711Abstract: Phosphomolybdic acid and partial alkali salts of phosphomolybdic acid are used as stabilizers for aqueous hydrogen peroxide.Type: GrantFiled: January 27, 2000Date of Patent: April 30, 2002Assignee: Crompton CorporationInventors: Peter Frenkel, Ted M. Pettijohn
-
Publication number: 20020042440Abstract: An emulsifiable composition for the control of insects, especially of termites, comprising as active ingiedients a 1-substituted phenyl 3-CN pyrazole and a weakly polar solvent and an emulsifying agent, and optionally some further additives or solvents. These compositions avoid the formation of crystals.Type: ApplicationFiled: August 22, 1997Publication date: April 11, 2002Inventors: TAKAAKI MIZUTANI, MICHIHIKO IKEDA, HIROSHI KODAMA, MASAKAZU SHIBAYAMA
-
Patent number: 6369112Abstract: The present invention is directed to a biguanide-containing disinfecting solution containing tyloxapol in combination with a poloxamine for stabilizing the biguanide, which is especially useful for contact-lens solutions that provide enhanced disinfecting and enhanced cleaning efficacy. The method of the present invention comprises cleaning and disinfecting a contact lens with the above-described solution.Type: GrantFiled: December 15, 1998Date of Patent: April 9, 2002Assignee: Bausch & Lomb IncorporatedInventor: Erning Xia
-
Patent number: 6369115Abstract: A dry powder formulation for treatment of pulmonary conditions, via inhalation, includes an effective amount of formoterol or a salt or solvate thereof, in a dry powder form, an effective amount of fluticasone, in a dry powder form, and an excipient. A method for preparing a physically stable dry powder formulation for inhalation includes the steps of micronizing a first active polar drug, a second active non-polar drug, and a polar excipient. The second non-polar active drug is first blended with the excipient to form an intermediate mixture. The intermediate mixture is then blended with the first active polar drug. The increased separation of the polar drug and polar excipient stabilizes the formulation.Type: GrantFiled: March 20, 2000Date of Patent: April 9, 2002Assignee: Dura Pharmaceuticals, Inc.Inventor: Gary Ward
-
Patent number: 6350467Abstract: A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.Type: GrantFiled: June 28, 1999Date of Patent: February 26, 2002Assignee: Antioxidant Pharmaceuticals Corp.Inventors: Harry B. Demopoulos, Myron L. Seligman
-
Patent number: 6346279Abstract: An acidic aqueous hydrogen peroxid solution is provided, with improved disinfectant activity. Concentrated solutions preferably contain up to about 8% and as-used concentrations contain about 0.5% peroxide. The solution also contains from 0.1 to 5.0% of at least one acid compound, e.g. phosphoric and/or a phosphonate with from 1 to 5 phosphonic acid groups, and from 0.02 to 5% of at least one anionic surfactant. The surfactant is selected from C8 to C16-alkyl aryl sulphonic acids, sulphonated C12 to C22 carboxylic acids, C8 to C22-alkyl diphenyl oxide sulphonic acids, naphthalene sulphonic acids, C8 to C22 alkyl sulphonic acids, and alkali metal and ammonium salts thereof, and alkali metal C8 to C18 alkyl sulphates, and mixtures thereof. Most preferably the solution has an emulsifier, e.g. a salt of an alkylated diphenyl oxide. The solution may also contain corrosion inhibitors and/or lower alcohols.Type: GrantFiled: July 19, 1999Date of Patent: February 12, 2002Assignee: Virox Technologies, Inc.Inventor: Michael J. Rochon
-
Publication number: 20010042936Abstract: A process for producing solid creatine-containing dosage forms, whereinType: ApplicationFiled: April 5, 2001Publication date: November 22, 2001Inventors: Knut Kessel, Gunter Scherr, Thomas Bogenstatter, Gunther Berndl, Jorg Breitenbach
-
Patent number: 6316453Abstract: Difficulties in preparing a stable pharmaceutical composition containing 5-Isopropyl-pyridine-2-sulfonic acid 6-(2-hydroxy-ethoxy)-5(2-methoxy-phenoxy)2-(2-1H-tetrazol-5-yl-pyridin-4yl)-pyrimidin-4-ylamide in form of the water soluble disodium salt, a buffer and preferably a metal complex forming agent, have been encountered. It was unexpectedly found that these difficulties can be overcome by adjusting the pH of the solution with an acid to over and above 8,2, preferably to 9,0, but not higher than 10.Type: GrantFiled: May 18, 2000Date of Patent: November 13, 2001Assignee: Actelion Pharmaceuticals Ltd.Inventor: Peter Loeliger
-
Patent number: 6306905Abstract: The present invention relates to stable aqueous formulations of the insect repellent ethyl 3-(N-butyl-acetamino)propionate.Type: GrantFiled: July 23, 1999Date of Patent: October 23, 2001Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Thekla Kurz, Sabine Hitzel, Dorothee Wille, Mohammad Jalalian
-
Patent number: 6287600Abstract: A pharmaceutical composition is provided for the oral administration of an NSAlD and a prostaglandin. The composition is a solid dosage form wherein the NSAID is enterically coated and the prostaglandin is present along with an effective stabilizing amount of a prostaglandin stabilizing agent such as hydroxypropyl methylcellulose or polyvinylpyrrolidone. Exemplary dosage forms are bilayer tablets in which the prostaglandin is misoprostol and the NSAID is diclofenac, piroxicam, or a pharmaceutically acceptable salt thereof. Methods for using the composition to treat NSAID-responsive conditions, disorders and diseases are provided as well.Type: GrantFiled: March 20, 2000Date of Patent: September 11, 2001Assignee: Pharmascience Inc.Inventors: Aomar Ouali, Abul Kalam Azad
-
Patent number: 6284288Abstract: The use of silica for controlling the thermal degradation of bicarbonate of an alkaline, alkaline-earth metal or bicarbonate of ammonia with an average particle size less than or equal to 100 &mgr;m is disclosed. The resulting bicarbonate and silica mixtures may be used in cosmetics and detergents, and more particularly in formulae for toothpaste.Type: GrantFiled: May 25, 1999Date of Patent: September 4, 2001Assignee: NovacarbInventors: Michel Gubelmann, Michel Seguin
-
Patent number: 6277414Abstract: The present invention relates to an aqueous decontaminating composition comprising (A) an amount of H2O2 less than or equal to 60% by weight, based on the total weight of said composition; (B) an RCO3H/RCO2H mixture, where R is methyl or ethyl, as indicated above, said mixture being present in an amount such that the weight ratio of said mixture to the hydrogen peroxide is between 0.15/1 and 0.85/1; (C) a silver component as a source of Ag ions, selected from the group consisting of silver salts and complexes, said silver component being present in an amount such that the weight ratio of said silver component to the hydrogen peroxide is between 0.0005/1 and 0.015/1; (D) a stabilizer present in an amount such that the weight ratio of said stabilizer to the hydrogen peroxide is between 0.0005/1 and 0.025/1; and water to make up to 100% by weight. It further relates to the method of preparation and to the use of said composition.Type: GrantFiled: September 22, 1998Date of Patent: August 21, 2001Assignee: SodifraInventors: Alain Elhaik, Raphaƫl Alex De Nicola
-
Patent number: 6274161Abstract: Disclosed is a composition for human consumption comprising creatine suspended in an edible supporting matrix, a method of making the composition, and a method of stably storing creatine-containing foodstuffs at ambient temperature.Type: GrantFiled: October 18, 1999Date of Patent: August 14, 2001Assignee: The Howard FoundationInventors: Alan N Howard, Roger C Harris
-
Patent number: 6274553Abstract: A method is provided for elevating the stability of peptides containing the sequence -Asp-Gly- or -Asn-Gly- by preventing these sequences from changing into succinimide compounds or &bgr;-transition compounds. The method comprises adding an organic acid to a solution of peptides containing these sequences to bring the pH value of the solution to a pH of between 5 and 6.5 followed by freeze-drying. In one embodiment, sucrose or mannitol is added together with the organic acid. Freeze-dried medicinal compositions obtained by using the method have excellent stability. In one embodiment of the invention, compositions produced by the method are provided and comprise hirudin or hirudin variants.Type: GrantFiled: December 21, 1999Date of Patent: August 14, 2001Assignee: Japan Energy CorporationInventors: Hideyuki Furuya, Hiroyuki Morita, Yukitaka Takatsu, Kose Michibuchi, Makoto Tanigawa
-
Patent number: 6270805Abstract: A once-a-day controlled release formulation of a water soluble drug is described which includes: (a) from 20 to 50% by weight of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a binder; and a second layer which comprises a membrane comprising a pH dependent polymeric material; and (b) from 50% to 80% by weight of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a binder and a second layer which comprises a polymeric membrane and a alkaline earth metal stearate which will substantially maintain its integrity in the varying pH conditions of the gastrointestinal tract but is permeable to said water soluble drug; and (c) a unit dose containment system.Type: GrantFiled: November 6, 1998Date of Patent: August 7, 2001Assignee: Andrx Pharmaceuticals, Inc.Inventors: Chih-Ming Chen, Xiu Xiu Cheng
-
Publication number: 20010007681Abstract: A controlled release diltiazem dosage formulation comprising a plurality of active pellets coated with an extended release coating wherein the active pellets contain diltiazem or a pharmaceutically acceptable salt, a pharmaceutically acceptable inert seed and a binder and the extended release coating contains a water insoluble water permeable polymer, a channeling agent, a lubricant and optionally a surfactant. A single batch intermittent method of manufacturing a heterogeneous population of extended release pellets for use as a dosage formulation is also disclosed.Type: ApplicationFiled: July 20, 1998Publication date: July 12, 2001Inventors: CHIH-MING CHEN, XIU XIU CHENG, STEVE JAN
-
Patent number: 6255350Abstract: This invention relates to a single phase emulsifiable concentrate composition comprising (a) between about 0.05 and about 25 wt. % of a biologically, fungicidally and/or herbicidally active aza compound; (b) between about 2 and about 40 wt. % of a lactam selected from the group of N-methyl pyrrolidone, N-methyl caprolactam, a C8 to C18 alkyl pyrrolidone, a C8 to C18 caprolactam and a mixture thereof; (c) between about 2 and about 20 wt. % of a moisture scavenging agent selected from the group consisting of a liquid molecularly hindered carbodiimide, a molecular sieve or a mixture thereof and (d) between about 10 and about 80 wt. % of a mixture of at least two non-ionic surfactants having an overall hydrophilic/lipophilic balance (HLB) above 7. The invention also relates to the stable oil-in-water (o/w) miniemulsions prepared from the above by dilution to between about 40 and about 99.99 wt. % water for a “pour on”, dip or spray solution useful in the treatment of animals or plants.Type: GrantFiled: October 9, 1998Date of Patent: July 3, 2001Assignee: ISP Investments Inc.Inventors: Domingo I. Jon, Donald I. Prettypaul, Matthew J. Benning, Kolazi S. Narayanan, Robert M. Ianniello
-
Patent number: 6255331Abstract: Disclosed are biocidal compositions comprising mixtures of formaldehyde-releasing imidazolidines, such as 1,3-dimethylol-5,3-dimethylhydantoin, and 3-isothiazolones stabilized with low levels of copper salts.Type: GrantFiled: August 16, 2000Date of Patent: July 3, 2001Assignee: Rohm and Haas CompanyInventors: Beverly Jean El A'mma, Susan Lynn Nagahashi
-
Patent number: 6251415Abstract: A novel three component solvent system consisting of glyceryl triacetate, a substituted biphenyl, and a mixture of isoparafinic hydrocarbons is disclosed. The system is useful in the formulation of pesticides, and the use of the system to prepare emulsifiable concentrates and microemulsions is exemplified.Type: GrantFiled: October 27, 1997Date of Patent: June 26, 2001Assignee: FMC CorporationInventor: Richard M. Herbert
-
Patent number: 6218375Abstract: A ras-farnesyltransferase inhibitor complex formed of ras-farnesyltransferase inhibitor or a pharmaceutically acceptable salt thereof, of the formula I wherein n is 0 or 1; R1 is selected from Cl, Br, phenyl, pyridyl or cyano; R2 is aralkyl; R3 is selected from lower alkyl, aryl or substituted aryl or heterocyclo; Z1 is selected from CO, SO2, CO2, or SO2NR5, R5 is selected from hydrogen, lower alkyl or substituted alkyl; and sulfobutylether-7-&bgr;-cyclodextrin or 2-hydroxypropyl-&bgr;-cyclodextrin is provided. The complex has unexpectedly high aqueous solubility of the ras-farnesyltransferase inhibitor and is useful for its intravenous delivery to humans with cancer. Also provided is a method for forming the complex. The ras-farnesyltransferase inhibitors are useful as anti-tumor agents.Type: GrantFiled: January 17, 2000Date of Patent: April 17, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Krishnaswamy S. Raghavan, Timothy M. Malloy, Sailesh A. Varia
-
Patent number: 6210657Abstract: Isoindolinone derivatives of the formula I, in which the variables have the following meanings: R1 is hydrogen, COOR4, COR4, CONR4R5, CN, C1-C20-alkyl, C2-C10-alkenyl, C3-C10-cycloalkyl, C3-C10-cycloalkenyl, aryl or heteroaryl, substituted or unsubstituted; R1 and R2 together are C7-C10-bicycloalkyl or C7-C10-bicycloalkenyl; R3 is hydrogen, C1-C20-alkyl, C2-C10-alkenyl, C3-C10-cycloalkyl, C3-C10-cycloalkenyl, C1-C12-alkoxy, C1-C20-alkoxycarbonyl, C1-C12-alkylamino, C1-C12-dialkylamino, aryl or heteroaryl, substituted or unsubstituted, substituents which confer solubility in water, selected from the group consisting of carboxylate, sulfonate or ammonium radicals; R4 and R5 independently of one another are hydrogen, C1-C20-alkyl, C2-C10-alkenyl, C3-C10-cycloalkyl, C3-C10-cycloalkenyl; aryl or heteroaryl, substituted or unsubstituted; are used as stabilizers for organic materials.Type: GrantFiled: December 9, 1998Date of Patent: April 3, 2001Assignee: BASF AktiengesellschaftInventors: Thorsten Habeck, Sylke Haremza, Hubert Trauth, Volker Schehlmann, Horst Westenfelder
-
Patent number: 6211213Abstract: Stable microbicidal compositions containing a 3-isothiazolone compound, organic oxidants, copper salts and water are disclosed. Also disclosed are methods of stabilizing 3-isothiazolone compositions.Type: GrantFiled: April 12, 2000Date of Patent: April 3, 2001Assignee: Rohm and Haas CompanyInventor: Beverly Jean El A'mma
-
Patent number: 6197781Abstract: A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.Type: GrantFiled: August 13, 1999Date of Patent: March 6, 2001Assignee: Novartis AGInventors: Patrice Guitard, Barbara Haeberlin, Rainer Link, Friedrich Richter
-
Patent number: 6197813Abstract: Liquid vitamin C concentrate compositions comprise a mineral ascorbate and a pharmacologically acceptable liquid organic polyol solvent for the mineral ascorbate, the concentrate having a pH between about 5 and 7. The concentrate may also contain an aldonic compound and/or a pharmacologically acceptable zinc compound. The concentrate compositions are prepared by heating the solvent to 50-90° C. and mixing the ascorbate and/or aldonic compound and/or zinc compound into the heated solvent, preferably in the absence of oxygen. These concentrate compositions are also characterized as a composition which comprises the reaction product of a mineral ascorbate and a pharmacologically acceptable liquid organic polyol solvent and, optionally an aldonic compound and/or a soluble non-toxic zinc compound, which reaction product includes 4-hydroxy-5-methyl-3(2H)-furanone and/or 3-hydroxy kojic acid.Type: GrantFiled: June 15, 1999Date of Patent: March 6, 2001Assignee: Oxycal Laboratories, Inc.Inventor: John C. Hegenauer
-
Patent number: 6194001Abstract: Provided are tablet formulations in one embodiment comprising clavulanic acid or salt thereof, amoxycillin, and trehalose. The trehalose is, for example, amorphous anhydrous trehalose. The amorphous anhydrous trehalose is present in an amount, for example, of 5 to 50%. The formulation may further comprise, for example, desiccants, such as silica gel, or lubricants.Type: GrantFiled: June 23, 1999Date of Patent: February 27, 2001Assignee: Quadrant Holdings Cambridge Ltd.Inventors: Enda Martin Gribbon, Glen Patrick Martyn, Camilo Anthony Leo Selwyn Colaco
-
Patent number: 6194002Abstract: A pharmaceutical composition in solid dosage form comprising bupropion hydrochloride as active drug and fumaric acid as stabilizer.Type: GrantFiled: August 5, 1999Date of Patent: February 27, 2001Inventor: Bernarad Charles Sherman
-
Patent number: 6187339Abstract: The invention concerns a solid pharmaceutical composition comprising less than 7% by weight of an oil or oily substance, a low dosage active ingredient, and a water insoluble non-cross-linked polymeric excipient capable of binding water and having a mean particle size greater than 150 &mgr;m. The composition can be obtained by a simple procedure comprising mixing the water insoluble non-cross-linked polymeric excipient capable of binding water and the active ingredient, which is dissolved or dispersed in an oil or an oily substance, in an aqueous dispersion thereof, or in water.Type: GrantFiled: October 17, 1995Date of Patent: February 13, 2001Assignee: Akzo Nobel N.V.Inventors: Pieter de Haan, Henrika Gerardina Maria Poels-Janssen
-
Patent number: 6184220Abstract: The present invention relates to orally administered suspensions of pharmaceutical active substances of the NSAID type, particularly the antirheumatic agent Meloxicam, which are stabilized by the addition of small amounts of highly dispersed silicon dioxide using high shear forces and adding small amounts of hydrophilic polymers to form a three-dimensional siloid structure, and a process for the preparation thereof.Type: GrantFiled: March 25, 1999Date of Patent: February 6, 2001Assignee: Boehringer Ingelheim Pharma KGInventors: Dietrich TĆ¼rck, Veit Schmelmer
-
Patent number: 6183779Abstract: A pharmaceutical composition is provided for the oral administration of an NSAID and a prostaglandin. The composition is a solid dosage form wherein the NSAID is enterically coated and the prostaglandin is present along with an effective stabilizing amount of a prostaglandin stabilizing agent such as hydroxypropyl methylcellulose or polyvinylpyrrolidone. Exemplary dosage forms are bilayer tablets in which the prostaglandin is misoprostol and the NSAID is diclofenac, piroxicam, or a pharmaceutically acceptable salt thereof. Methods for using the composition to treat NSAID-responsive conditions, disorders and diseases are provided as well.Type: GrantFiled: March 22, 1999Date of Patent: February 6, 2001Assignee: Pharmascience Inc.Inventors: Aomar Ouali, Abul Kalam Azad
-
Patent number: 6168808Abstract: Composition in the form of an aqueous solution, useful for disinfecting hard surfaces comprises: a) from 0.0005% to 20% by weight of peracetic acid, b) from 0.001% to 45% by weight of acetic acid, c) from 0.001% to 35% by weight of hydrogen peroxide, d) from 0.0001% to 2% by weight of at least one compound of formula (I) (R1) (R2) (R3)N→O (I) e) if desired, up to 2.5% by weight of at least one nonionic surfactant, and wherein f) the weight ratio between the compound of formula (I) and the peracetic acid is less than or equal to 1, and in that g) the weight ratio between the nonionic surfactant and the peracetic acid is less than or equal to 0.2.Type: GrantFiled: April 24, 1998Date of Patent: January 2, 2001Assignees: Chemoxal SA, Societe d'Exploitation de Produits pour les Industries Chimiques SeppicInventors: Catherine Hamon Godin, Yves Gouges, Daniel Le Rouzic
-
Patent number: 6168802Abstract: Disclosed are compositions which include creatine and Aloe Vera extract, for the purpose of increasing the creatine supply deposits of human beings, and to improve their intestinal health. The composition is presented as a drink, either constituted from a dry powder or in liquid form. Also disclosed is a method of increasing the stability of a drink or semi-liquid solid comprising creatine and Aloe Vera extract by storing the compositions below ambient temperature, preferably 0-8° C.Type: GrantFiled: June 2, 1999Date of Patent: January 2, 2001Assignee: The Howard FoundationInventors: Alan Norman Howard, Roger Harris
-
Patent number: 6166025Abstract: The present invention provides an aqueous pharmaceutical composition comprising 5 to 200 mg/ml of eletriptan hemisulfate and from 0.5 to 2.0% weight/volume of caffeine.Type: GrantFiled: January 27, 2000Date of Patent: December 26, 2000Assignee: Pfizer Inc.Inventors: Valerie Denise Harding, Anne Billotte
-
Patent number: 6165505Abstract: A water soluble effervescent table formulation for preparing a disinfecting solution comprising a first tablet containing a bromide releasing agent and a second tablet containing a hypochlorite releasing agent.Type: GrantFiled: August 17, 1998Date of Patent: December 26, 2000Assignee: Chem-Link Laboratories, LLCInventors: Richard A. DeSenna, Hilton Dawson
-
Patent number: 6159500Abstract: A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.Type: GrantFiled: December 31, 1997Date of Patent: December 12, 2000Assignee: Antioxidant Pharmaceuticals CorporationInventors: Harry B. Demopoulos, Myron L. Seligman
-
Patent number: 6159499Abstract: The present invention relates to a composition, particularly adapted to oral administration, substantially free of alkaline-reacting compounds. The composition comprises (a) a core containing an acid-labile benzimidazole active principle, where the core comprises a plurality of nuclei and the active principle mixed together and then compressed together, and where the active principle is not in the form of an alkaline salt; (b) an intermediate layer; and (c) an enteric layer; provided that omeprazole is not the benzimidazole active principle. A process for preparing the composition is also disclosed.Type: GrantFiled: October 20, 1998Date of Patent: December 12, 2000Assignee: Pharma Pass LLCInventor: Pawan Seth
-
Patent number: 6156341Abstract: Pharmaceutical agents that contain a gallic acid ester as an antioxidant in combination with a steroidal active ingredient, their production and their use.Type: GrantFiled: July 2, 1997Date of Patent: December 5, 2000Assignee: Schering AktiensgesellschaftInventors: Thomas Backensfeld, Ralph Lipp, Susanne Keitel
-
Patent number: 6153644Abstract: A stabilized, injectable pharmaceutical composition for human administration comprises (a) an antineoplastic compound,(b) a solubilizing/dispersing agent, and (c) a stabilizing amount of an anti-oxidant.Type: GrantFiled: November 2, 1999Date of Patent: November 28, 2000Assignee: Mylan Pharmaceuticals, Inc.Inventors: Walter H. Owens, Timothy A. Irby
-
Patent number: 6153223Abstract: The present invention pertains to a stabilized pharmaceutical composition which comprises a mixture of (a) a pharmaceutical agent unstable at a pH above about 3.5; and (b) a stabilizing amount of an acidic pharmaceutically acceptable carrier to stabilize the pharmaceutical agent. The acidic pharmaceutically acceptable carrier is a dried premixture of a pharmaceutically acceptable carrier and an aqueous solution of an acid. The stabilized pharmaceutical composition has a pH value of less than about 3.5, and when stored at a temperature of about 50.degree. C. for about 4 weeks at about 27% relative humidity, retains at least about 80% of the pharmaceutical agent. This invention also pertains to sustained-release forms of the stabilized pharmaceutical compositions as well as to novel methods for preparing and using the stabilized pharmaceutical compositions and to stabilized pharmaceutical compositions made by the novel method.Type: GrantFiled: June 5, 1998Date of Patent: November 28, 2000Assignee: Watson Pharmaceuticals, Inc.Inventors: Vahe Henry Apelian, Nilesh H. Parikh, Raman Iyer
-
Patent number: 6136833Abstract: Provided is a pharmaceutical composition comprising a tablet or capsule containing a pharmacologically effective amount of a pharmaceutical compound, or a pharmaceutically acceptable salt thereof, having an amidine-based group and an optional ester group, a pharmaceutically acceptable solid carrier, and a pharmaceutically acceptable acid in an amount to modify the pH of the composition to substantially that of the compound at pH of maximum stability.Such a composition is prepared by adding water during formulation manufacture and contacting the compound during formulation manufacture with a pharmaceutically acceptable acid having a pH in a saturated aqueous solution substantially that of the compound at pH of maximum stability.Type: GrantFiled: January 11, 1999Date of Patent: October 24, 2000Assignee: Dupont Pharmaceuticals CompanyInventors: Sherif Ibrahim Farag Badawy, Donna Lynn Gilbert
-
Patent number: 6130253Abstract: Pesticides for the extermination of terrestrial arthropods are disclosed which comprise formulations of a combination of terpenes in aqueous solutions which may be used together with citral. No resistance to the formulations of the invention has been seen. When used on the scalp or body for lice infestation no extended dwell time is required. The formulations do not have unpleasant odors. The formulations are directed towards providing topical preparations which may be used on the skin, scalp and hairy body parts of humans and animals, sprays for use directly against terrestrial arthropods, a dipping solution for combs and a laundry additive, amongst others.Type: GrantFiled: August 23, 1999Date of Patent: October 10, 2000Assignee: XiMed Group PLCInventors: Lanny Udell Franklin, Gary David Cunnington, David E. Young
-
Patent number: 6126962Abstract: A stable crystalline powdery saccharide having a crystallinity of 40% or more, less hygroscopicity, satisfactory fluidity, and beneficial handleability, which is obtainable from an aqueous solution, containing trehalose and a different saccharide(s) crystallizable in the presence of trehalose, by crystallizing the trehalose along with the different saccharide(s).Type: GrantFiled: December 23, 1998Date of Patent: October 3, 2000Assignee: Kabushiki Kaisha Hayashibara Seibutus Kagaku KenkyujoInventors: Hiroto Chaen, Kazuhisa Mukai, Toshio Miyake
-
Patent number: 6126971Abstract: An oral pharmaceutical composition is provided for treating hypercholestereolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) ##STR1## with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.Type: GrantFiled: July 2, 1997Date of Patent: October 3, 2000Assignee: Warner-Lambert CompanyInventors: Nancy Mills, Nouman A. Muhammad, Jay Weiss, Russell U. Nesbitt
-
Patent number: 6123966Abstract: A stabilized two-part disinfecting system comprising a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition. The first part contains a non-esterifying acid and an alcohol-containing humectant or antifreeze, while the second part contains a salt of an organic acid and an optional metal chlorite. Methods for making a disinfecting composition by mixing the two-part disinfecting system, as well as for disinfecting substrates by contact therewith, are also disclosed.Type: GrantFiled: September 3, 1998Date of Patent: September 26, 2000Assignee: Alcide CorporationInventor: Robert D. Kross
-
Patent number: 6114324Abstract: For the oral administration of the anti-depressant mirtazapine an aqueous solution or suspension is found which is preferably stabilized by methionine, is thickened, and which has a pH of from 2.5 to 3. By the formulation according to the invention, an undesirable local anaesthetic effect of mirtazapine is avoided.Type: GrantFiled: July 22, 1999Date of Patent: September 5, 2000Assignee: Akzo Nobel, N.V.Inventors: Arnold Titus Philip Skrabanja, Robert Edward Tully
-
Patent number: 6110476Abstract: A synegistic system based on a phosphonic acid derivative and on a metabisulphite, for stabilizing ascorbic acid. The invention also relates to compositions, in particular cosmetic and dermatological compositions, containing ascorbic acid and this stabilizing system, and to the use of these compositions in the cosmetics and/or dermatological fields.Type: GrantFiled: September 2, 1998Date of Patent: August 29, 2000Assignee: L'OrealInventors: Quang Lan Nguyen, Isabelle Afriat, Dang-Man Pham, Florence Chanvin
-
Patent number: 6103769Abstract: Disclosed are pharmaceutical composition of a sterile, injectable physiologically acceptable solution containing nitric oxide (NO), processes for preparing the compositions and a process for detecting physiologically present NO. With these NO solutions, NO in high doses can trigger locally in vessels, e.g. coronary vessels, specific local biological effects such as relaxation of the smooth vascular musculature, inhibition of thee adhesion of thrombocytes, etc., without producing systemic side-effects, such as for example, a critical drop in blood pressure, in spite of the high does. The detection process enables the presence of an endothelial dysfunction to be established from the whole blood of humans and other mammals.Type: GrantFiled: July 30, 1998Date of Patent: August 15, 2000Assignee: Schwarz Pharma AGInventor: Malte Kelm
-
Patent number: 6096348Abstract: A low odor, aqueous, quick acting cold temperature disinfectant solution primarily useful for medical instruments to disinfect within a half hour or less. The composition comprises a reacting or synergistic combination of hydrogen peroxide and from about 1% to 30% by weight of a carboxylic acid/carboxylate salt buffered solution.Type: GrantFiled: July 29, 1998Date of Patent: August 1, 2000Assignee: Healthpoint, Ltd.Inventors: Norman A. Miner, William H. Woller, Edward L. Anderson, David W. Hobson
-
Patent number: 6080793Abstract: Cosmetic/pharmaceutical/hygienic compositions (e.g., lipcolors) are formulated as homogeneous and stable, supple dough extrudates, said supple dough extrudates having at least one thermally-unmodified but normally heat-sensitive compound (for example a volatile compound and/or a compound having a low flash point) and at least one elevated melting temperature T compound (for example a wax) homogeneously distributed therethrough.Type: GrantFiled: June 9, 1999Date of Patent: June 27, 2000Assignee: Societe L'Oreal S.A.Inventor: Isabelle Agostini